NWCI Stock Overview
A cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NewCardio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -99.92% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NWCI | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | 8.9% | 1.2% |
| 1Y | n/a | 8.7% | 21.0% |
Return vs Industry: Insufficient data to determine how NWCI performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how NWCI performed against the US Market.
Price Volatility
| NWCI volatility | |
|---|---|
| NWCI Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NWCI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NWCI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Jess Jones | n/a |
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data.
NewCardio, Inc. Fundamentals Summary
| NWCI fundamental statistics | |
|---|---|
| Market cap | US$40.00 |
| Earnings (TTM) | -US$8.84m |
| Revenue (TTM) | US$238.58k |
0.0x
P/S Ratio0.0x
P/E RatioIs NWCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWCI income statement (TTM) | |
|---|---|
| Revenue | US$238.58k |
| Cost of Revenue | US$167.77k |
| Gross Profit | US$70.81k |
| Other Expenses | US$8.91m |
| Earnings | -US$8.84m |
Last Reported Earnings
Sep 30, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NWCI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 01:46 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2011/09/30 |
| Annual Earnings | 2010/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NewCardio, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Ryan McGaver | Capstone Investments |